S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
NASDAQ:PTCT

PTC Therapeutics Stock Forecast, Price & News

$37.93
+0.95 (+2.57%)
(As of 12/7/2021 04:00 PM ET)
Add
Compare
Today's Range
$37.49
$38.85
50-Day Range
$35.36
$41.59
52-Week Range
$34.85
$70.82
Volume
513,513 shs
Average Volume
508,579 shs
Market Capitalization
$2.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.89
30 days | 90 days | 365 days | Advanced Chart
Receive PTCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


PTC Therapeutics logo

About PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Headlines

PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up to $38.84
November 17, 2021 |  americanbankingnews.com
Is Therapeutics (NASDAQ:PTCT) Weighed On By Its Debt Load?
November 8, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTCT
Employees
963
Year Founded
N/A

Sales & Book Value

Annual Sales
$380.77 million
Book Value
$1.48 per share

Profitability

Net Income
$-438.16 million
Pretax Margin
-89.68%

Debt

Price-To-Earnings

Miscellaneous

Free Float
67,163,000
Market Cap
$2.68 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/28/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

983rd out of 1,394 stocks

Pharmaceutical Preparations Industry

460th out of 673 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

Is PTC Therapeutics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTC Therapeutics stock.
View analyst ratings for PTC Therapeutics
or view top-rated stocks.

How has PTC Therapeutics' stock price been impacted by Coronavirus?

PTC Therapeutics' stock was trading at $47.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PTCT shares have decreased by 19.4% and is now trading at $37.93.
View which stocks have been most impacted by COVID-19
.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for PTC Therapeutics
.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its earnings results on Thursday, October, 28th. The biopharmaceutical company reported ($1.89) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.78) by $0.11. The biopharmaceutical company earned $139 million during the quarter, compared to analyst estimates of $118.87 million. PTC Therapeutics had a negative trailing twelve-month return on equity of 169.13% and a negative net margin of 92.43%. The company's revenue was up 68.1% on a year-over-year basis. During the same period in the prior year, the company posted ($1.03) earnings per share.
View PTC Therapeutics' earnings history
.

What price target have analysts set for PTCT?

10 brokers have issued 1-year price objectives for PTC Therapeutics' stock. Their forecasts range from $38.00 to $75.00. On average, they expect PTC Therapeutics' share price to reach $54.13 in the next twelve months. This suggests a possible upside of 42.7% from the stock's current price.
View analysts' price targets for PTC Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the following people:
  • Stuart Walter Peltz, Chief Executive Officer & Director
  • Emily Hill, Chief Financial Officer
  • Neil Gregory Almstead, Chief Technical Operations Officer
  • Mark Jerome Pykett, Chief Scientific Officer
  • Mark Elliott Boulding, Chief Legal Officer & Executive Vice President (LinkedIn Profile)

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics CEO Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among PTC Therapeutics' employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (12.40%), BlackRock Inc. (9.20%), Franklin Resources Inc. (6.81%), Janus Henderson Group PLC (5.06%), Macquarie Group Ltd. (2.22%) and Geode Capital Management LLC (1.81%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Marcio Souza, Mark Elliott Boulding, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends for PTC Therapeutics
.

Which institutional investors are selling PTC Therapeutics stock?

PTCT stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Point72 Asset Management L.P., Balyasny Asset Management LLC, Balyasny Asset Management LLC, Renaissance Technologies LLC, Natixis, Sectoral Asset Management Inc, and Caption Management LLC. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey, and Stuart Walter Peltz.
View insider buying and selling activity for PTC Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying PTC Therapeutics stock?

PTCT stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Macquarie Group Ltd., Asymmetry Capital Management L.P., Janus Henderson Group PLC, UBS Group AG, Russell Investments Group Ltd., Hsbc Holdings PLC, and Wellington Management Group LLP.
View insider buying and selling activity for PTC Therapeutics
or or view top insider-buying stocks.

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $37.93.

How much money does PTC Therapeutics make?

PTC Therapeutics has a market capitalization of $2.68 billion and generates $380.77 million in revenue each year. The biopharmaceutical company earns $-438.16 million in net income (profit) each year or ($6.48) on an earnings per share basis.

How many employees does PTC Therapeutics have?

PTC Therapeutics employs 963 workers across the globe.

What is PTC Therapeutics' official website?

The official website for PTC Therapeutics is www.ptcbio.com.

Where are PTC Therapeutics' headquarters?

PTC Therapeutics is headquartered at 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at [email protected], or via fax at 908-222-7231.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.